Rotavirus - Simplified Virology, Statistics, Symptoms, Vaccination & Common FAQs

Loading...

Flash Player 9 (or above) is needed to view presentations.
We have detected that you do not have it on your computer. To install it, go here.

0 comments

Post a comment

    Post a comment
    Embed Video
    Edit your comment Cancel

    Favorites, Groups & Events

    Rotavirus - Simplified Virology, Statistics, Symptoms, Vaccination & Common FAQs - Presentation Transcript

    1. What are we talking about ?
      • A disease that affects ALL children before the age of 5 years
      • Responsible for 5 % deaths of all children less than 5 years.
    2. Rotavirus – in 4 parts Dr Gaurav Gupta Charak Clinics www.charakclinics.com DCH, DNB, MAAP, MIAP
    3. Rotavirus – the 4 parts
      • Virology – boring yet interesting !
      • Scary Statistics about Rotavirus – the Indian connection
      • Can we clinically identify Rotavirus Diarrhea
      • Preventing Rotavirus Diarrhea – what GSK wants me to talk about 
    4. Rotavirus Virology – Part 1
      • Rota – means wheel-like in greek
      • Double-stranded RNA virus
    5. Rotavirus – this is how it looks!
    6.  
    7. Rotavirus Virology
      • VERY resistant to destruction (Why is this important?)
      • VP4 antigen: P serotype; 11 human rotaviruses
      • VP7 antigen: G serotype; 10 human rotaviruses
      • Commonly found strains: P[8]G1; P[8]G3; P[8]G4; and P[4]G2
    8. Global distribution of human group A rotavirus P-G types (1989-2004) http://www.cdc.gov/ncidod/EID/vol4no4/parasharG.htm#fig%204) Other P[6]G8 Africa P[8]G5 Brazil P[11]G10 India P[6]G12 India
    9. Are these multiple serotypes important ?
      • NOT REALLY !
      • Because Natural RV infection attenuates
      • severity of subsequent infections, regardless
      • of serotype
    10. Cumulative probability of rotavirus infection in 200 Mexican infants during the 1st 2 years of life * *Complete protection against moderate-to-severe diarrhoea NEJM 1996; 335: 1022 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 Probability of rotavirus infection Age (months) 1st infection 2nd infection 3rd infection 4th infection 5th infection
    11. Scary Statistics– Part 2
      • Diarrhoea is third largest cause of death in under 5
      • Rotavirus are the single
      • most important cause of
      • diarrhoea worldwide.
      • Annually rotaviruses cause
        • 5% of all deaths in children
        • 527,000 deaths
          • 80% of deaths are in infancy
          • > 100,000 in India
        • 39% of childhood
        • hospitalisations for diarrhea
      Lancet Infect Dis 2007; 7: 56 Wkly Epidemiol Rec 2007; 82: 285 JID 2005; 192(Suppl 1) S1 EID 2006;12: 304
    12.  
    13.  
    14. Modified after Emerg Infect Dis 2006; 12: 304 5 million clinic visits 25 million domiciliary episodes 1 : 250 1 : 65 Event Risk of Particular Event 100,000 deaths 0.4 million hospitalisations 1 : 5 1 : 1 Estimated prevalence of rotavirus disease in India
    15.  
    16. Part 3 - Can we clinically diagnose Rotavirus gastroenteritis (RVGE)?
      • High fever and vomiting in a 6 month to 2 year child
      • Severe vomiting resistant to anti-emetics
      • Followed by explosive diarrhea, severe with significant peri-anal excoriation
      • The diarrhea can be mild to severe and generally lasts 3-9 days. Illness usually begins 3 days after exposure.
    17. When is a Viral GE unlikely?
      • Blood / WBCs in the stool
      • Persistent high fever
      • Persistent severe bilious vomit without diarrhea
    18.  
    19. Part 4 – Preventing rotavirus
      • Democratic Virus – affects the entire world equally, without differentiating the rich & poor – almost 40 % of hospital admissions worldwide due to diarrhea are due to RVGE.
      • Hand-washing and sanitation does not work due to the resistant nature of the virus.
      • Vaccine works well
    20. Vaccine development
      • Goals of a rotavirus vaccine
        • Aim to duplicate the degree of protection following natural infection
        • Prevent moderate to severe disease
          • Decrease numbers of children:
            • Dying from rotavirus disease
            • Admitted to hospital
            • Presenting to health care facilities
              • Hospital
              • Community
    21. What vaccines are available?
      • Rotashield (Wyeth) – Available in 1998, Animal Rhesus Monkey strain, withdrawn after 1 year due to clustering of cases of Intussusception.
      • Rotateq (Merck) – Pentavalent Bovine Live Attenuated vaccine.
          • > 70,000 subjects
          • Predominantly in the United States and Finland
          • No evidence for increased risk of intussusception
    22. Vaccines based upon human rotaviruses
      • A live-attenuated monovalent human rotavirus vaccine (Rotarix R ) P[8]G1
        • > 63,000 infants
        • Predominantly in 11 countries from Latin America
        • No evidence for increased risk of intussusception
        • Efficacy for rotavirus disease
          • 85% against severe rotavirus disease (81% after 1 dose)
          • 100% against the most severe dehydrating episodes
          • Protective efficacy against severe disease
            • Homotypic G1 serotype 92%
            • Homotypic P[8] non-G1 serotype 88%
      NEJM 2006; 354: 11
    23. 9% NEJM 2006; 354: 11 + 23 50-80% Post 1 st dose shedding N = 68,038 74 (67,79) 95 (91,97) 96 (90,98) 95 (92,97) 88 (<0,99) 93 (49,99) 89 (52,98) 100 (67,100) 59 (52,65) N = 20,169 ND 85 (72,92) 85 (70,94) 92 (74,98) 41 (-72,94) 88 (8,100) - 91 (62,99) 42 (29,53) Efficacy (95% CI) any disease severe hospitalisation Severe disease (95% CI) G1 G2 G3 G4 G9 All cause gastro admissions 3 2 Oral doses Bovine-human pentavalent P[8] G1-G4 Human monovalent P[8]G1 Origin RotaTeq TM Rotarix R
    24. Other vaccine candidates
      • Human-bovine reassortants
        • Bovine rotavirus tetravalent (BRV-TV) vaccine: G1-G4
          • Adding G8 + G9
          • Brazil, China and India
        • Naturally occurring human-bovine reassortants
          • Delhi (116E) neonatal strain P[10]G9 single bovine VP4 gene
          • Vellore (I321) neonatal strain P[11]G10
            • Bovine strain with 2 human-derived NSPs
              • Recently shown to be non-protective
      • Human neonatal rotavirus strains
        • Some strains appear naturally attenuated and protective
        • Melbourne neonatal RV3 strain P[6]G3
          • Low immunogenecity, but protective against disease in a small study
      JID 2006; 194: 370 Vaccine 2006; 24: 5817 Vaccine 2002; 20: 2950
    25. Cost Effectiveness of Rota Vaccine
      • A CMC Vellore study shows that average diarrhea hospitalization costs Rs. 4,000/- to 5,000/-
      • Rotavirus is a dehydrating diarrhea , with significant chances of doctor visit and hospitalization.
      • Vaccine is almost 90-100 % effective against severe RV diarrhea & hospitalization.
    26. Remember …..
      • Largest number of death in the WORLD due to Rotavirus occur in India. (More than 300 children/ day)
      • ORS is less likely to be effective in Rotavirus, due to increased tendency for vomiting, and destruction of intestinal villi by RV causing malabsorption of glucose, sodium and potassium.
    27. Common Questions
      • What is the maximum age for first dose?
      • What if the child vomits?
      • Can it be given with OPV/ Breast feed/ other vaccines?
      • How to best administer the vaccine?
      • Can Rotarix cause Intussusception?
      • Can we give one dose in children between 5-6 month? After 6 months?
      • How to counsel parents regarding this vaccine?
      • What are the contraindications for Rotavirus vaccine?
      • Let us ERADICATE
      • the thought of viral
      • diarrhea
    SlideShare Zeitgeist 2009

    + Gaurav GuptaGaurav Gupta Nominate

    custom

    579 views, 0 favs, 0 embeds more stats

    Rotavirus - Simplified Virology, Statistics, Sympto more

    More info about this document

    © All Rights Reserved

    Go to text version

    • Total Views 579
      • 579 on SlideShare
      • 0 from embeds
    • Comments 0
    • Favorites 0
    • Downloads 19
    Most viewed embeds

    more

    All embeds

    less

    Flagged as inappropriate Flag as inappropriate
    Flag as inappropriate

    Select your reason for flagging this presentation as inappropriate. If needed, use the feedback form to let us know more details.

    Cancel
    File a copyright complaint
    Having problems? Go to our helpdesk?

    Categories